<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000940.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;h1&gt;Aurora Kinase B and ZAK interaction model&lt;/h1&gt;


Equivalent of the stochastic model used in &amp;quot;Network pharmacology model predicts combined Aurora B and ZAK inhibition in MDA-MB-231 breast cancer cells&amp;quot;  by Tang et. al. 2018.

The only difference is cell division and partitioning of the components, which are available in the original model for SGNS2.&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer</ns3:title>
    <ns4:thumbnail xmlns:ns4="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000940.omex/curation_image.png"/>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns5:identifier xmlns:ns5="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/s41540-019-0098-z"/>
    <ns6:label xmlns:ns6="http://www.w3.org/2000/01/rdf-schema#">Jing Tang, Prson Gautam, Abhishekh Gupta, Liye He, Sanna Timonen, Yevhen Akimov, Wenyu Wang, Agnieszka Szwajda, Alok Jaiswal, Denes Turei, Bhagwan Yadav, Matti Kankainen, Jani Saarela, Julio Saez-Rodriguez, Krister Wennerberg &amp; Tero Aittokallio. Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. npj Systems Biology and Applications 5 (2019).</ns6:label>
  </rdf:Description>
</rdf:RDF>

